JAZZ
Jazz Pharmaceuticals plcCompany Information
- Company Name
- Jazz Pharmaceuticals plc
- CIK
- CIK0001232524
- Category
- Large accelerated filer
- Ticker: Exchange
- JAZZ: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- JAZZ
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-12
- Last sale
- 2026-09-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 331,371
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 60,985,940
- Shares outstanding
- 63,200,000
- Ownership
- 96.50%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- -2.80%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1,620 | 1,844 | 1,392 | 1,326 | 1,190 | 1,862 | 2,413 | 2,218 | 1,356 | 1,443 | 1,506 | 1,336 | ||||||
| Investments | 580 | 1,030 | 1,050 | 720 | 480 | 710 | 580 | 400 | 625 | 375 | 120 | 250 | ||||||
| Accounts Receivable Net Current | 881 | 836 | 831 | 764 | 714 | 653 | 717 | 724 | 698 | 707 | 706 | 628 | ||||||
| Inventory Net | 443 | 438 | 417 | 483 | 505 | 493 | 480 | 539 | 543 | 577 | 597 | 612 | ||||||
| Prepaid Expense Current | 200 | 150 | 152 | 147 | 164 | 150 | 177 | 155 | 134 | 123 | 185 | 110 | ||||||
| Other Assets Current | 245 | 285 | 324 | 315 | 298 | 260 | 262 | 354 | 326 | 315 | 321 | 310 | ||||||
| Assets Current | 3,968 | 4,583 | 4,166 | 3,756 | 3,350 | 4,128 | 4,629 | 4,390 | 3,682 | 3,540 | 3,435 | 3,246 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 212 | 203 | 200 | 189 | 185 | 179 | 173 | 176 | 169 | 166 | 170 | 222 | ||||||
| Operating Lease Right Of Use Asset | 52 | 56 | 59 | 61 | 63 | 49 | 54 | 77 | 73 | 62 | 65 | 65 | ||||||
| Intangible Assets Net Excluding Goodwill | 4,030 | 4,204 | 4,430 | 4,566 | 4,769 | 4,718 | 4,756 | 5,144 | 5,079 | 5,235 | 5,418 | 5,418 | ||||||
| Goodwill | 1,800 | 1,805 | 1,829 | 1,827 | 1,844 | 1,760 | 1,716 | 1,805 | 1,736 | 1,739 | 1,753 | 1,705 | ||||||
| Deferred Income Tax Assets Net | 926 | 907 | 869 | 846 | 603 | 575 | 560 | 583 | 545 | 508 | 478 | 464 | ||||||
| Deferred Finance Costs Noncurrent Net | 7 | 7 | 8 | 8 | 9 | 9 | 9 | 4 | 6 | 6 | 6 | 7 | ||||||
| Other Assets Noncurrent | 86 | 95 | 99 | 103 | 121 | 117 | 114 | 75 | 71 | 71 | 67 | 76 | ||||||
| Assets | 11,081 | 11,860 | 11,659 | 11,356 | 10,944 | 11,535 | 12,012 | 12,256 | 11,362 | 11,327 | 11,393 | 11,204 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 129 | 100 | 122 | 152 | 89 | 96 | 78 | 85 | 97 | 81 | 103 | 110 | ||||||
| Accrued Liabilities Current | 1,030 | 1,022 | 1,034 | 1,002 | 875 | 1,064 | 911 | 859 | 801 | 827 | 794 | 770 | ||||||
| Long Term Debt Current | 1,016 | 1,031 | 1,030 | 1,029 | 1,028 | 31 | 31 | 31 | 606 | 605 | 605 | 605 | ||||||
| Taxes Payable Current | 56 | 94 | 56 | 91 | 79 | 32 | 19 | 55 | 52 | 49 | 35 | 89 | ||||||
| Liabilities Current | 2,231 | 2,247 | 2,243 | 2,274 | 2,071 | 1,223 | 1,039 | 1,030 | 1,556 | 1,562 | 1,537 | 1,573 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Long Term Debt Noncurrent | 3,335 | 4,324 | 4,328 | 4,332 | 4,336 | 5,336 | 6,078 | 6,081 | 5,101 | 5,105 | 5,108 | 5,111 | ||||||
| Operating Lease Liability Noncurrent | 44 | 47 | 51 | 53 | 55 | 39 | 39 | 71 | 68 | 56 | 59 | 62 | ||||||
| Deferred Income Tax Liabilities Net | 529 | 548 | 594 | 629 | 682 | 671 | 677 | 792 | 775 | 810 | 848 | 841 | ||||||
| Other Liabilities Noncurrent | 141 | 162 | 125 | 109 | 94 | 91 | 87 | 111 | 99 | 97 | 105 | 127 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 4,332 | 4,244 | 4,240 | 4,086 | 4,000 | 3,925 | 3,914 | 3,838 | 3,779 | 3,714 | 3,700 | 3,640 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -663 | -651 | -569 | -570 | -486 | -786 | -948 | -603 | -888 | -882 | -842 | -1,035 | ||||||
| Retained Earnings Accumulated Deficit | 1,132 | 939 | 646 | 443 | 191 | 1,035 | 1,127 | 936 | 871 | 864 | 879 | 884 | ||||||
| Stockholders Equity | 4,802 | 4,532 | 4,319 | 3,959 | 3,706 | 4,175 | 4,094 | 4,171 | 3,763 | 3,696 | 3,737 | 3,489 | ||||||
| Liabilities And Stockholders Equity | 11,081 | 11,860 | 11,659 | 11,356 | 10,944 | 11,535 | 12,012 | 12,256 | 11,362 | 11,327 | 11,393 | 11,204 | ||||||
| Allowance For Doubtful Accounts Receivable Current | - | - | 17 | - | - | - | 33 | - | - | - | 21 | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | 300 | - | - | - | 300 | - | - | - | 300 | - | ||||||
| Common Stock Shares Issued | - | - | 61 | - | - | - | 61 | - | - | - | 62 | - | ||||||
| Shares Outstanding | - | - | 61 | - | - | - | 61 | - | - | - | 62 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJazz Pharmaceuticals plc (JAZZ) — SEC Financial Statements & Analysis
Jazz Pharmaceuticals plc (JAZZ) is a pharmaceutical preparations company, incorporated in L2. Jazz Pharmaceuticals plc trades on Nasdaq as: JAZZ. Jazz Pharmaceuticals plc (JAZZ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Jazz Pharmaceuticals plc carries a market cap of $15.23B, a P/E ratio of 16.19x, a P/B ratio of 3.17x, a P/S ratio of 3.31x, an enterprise value of $17.96B, and an EV/EBITDA multiple of 19.22x. On profitability, it posts an operating margin of 19.49%, a net margin of 20.45%, a Return on Equity (ROE) of 22.11%, a Return on Assets (ROA) of 8.54%, and a Return on Invested Capital (ROIC) of 11.51%. Per share, it reports EPS of $14.89, diluted EPS of $13.56, free cash flow per share of $25.18, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.59% year-over-year, net income growth of -332.38% year-over-year, and EPS growth of -325.03% year-over-year. On the balance sheet, it maintains a current ratio of 1.78x, a quick ratio of 1.49x, working capital of $1.74B, a debt-to-equity ratio of 0.46x, a debt ratio of 0.2, an interest coverage ratio of 5.25x, free cash flow of $1.59B (TTM), and net debt of $2.73B. Figures sourced from SEC EDGAR.
- Market Cap
- $15.23B
- P/E TTM
- 16.19x
- EPS TTM
- $14.89
- P/B TTM
- 3.17x
- ROE TTM
- 22.11%
- ROA TTM
- 8.54%
- Debt To Equity
- 0.46x
- Free Cash Flow TTM
- $1.59B
- Net Revenue TTM Growth 1Y
- 12.59%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Jazz Pharmaceuticals plc in?
Jazz Pharmaceuticals plc (JAZZ) operates in the Pharmaceutical Preparations industry.
What exchange does JAZZ trade on?
Jazz Pharmaceuticals plc (JAZZ) trades on the Nasdaq.
Where is Jazz Pharmaceuticals plc incorporated?
Jazz Pharmaceuticals plc is incorporated in Ireland.
When was Jazz Pharmaceuticals plc (JAZZ)'s most recent SEC filing?
Jazz Pharmaceuticals plc (JAZZ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is JAZZ's market cap?
Jazz Pharmaceuticals plc (JAZZ) has a market capitalization of $15.23B as of 2026-06-30.
What is JAZZ's P/E ratio?
Jazz Pharmaceuticals plc (JAZZ)'s trailing twelve month P/E ratio is 16.19x as of 2026-06-30.
What is JAZZ's EPS (earnings per share)?
Jazz Pharmaceuticals plc (JAZZ)'s trailing twelve month EPS is $14.89 as of 2026-06-30.
What is JAZZ's ROE (return on equity)?
Jazz Pharmaceuticals plc (JAZZ)'s trailing twelve month Return on Equity (ROE) is 22.11% as of 2026-06-30.
What is JAZZ's ROA (return on assets)?
Jazz Pharmaceuticals plc (JAZZ)'s trailing twelve month Return on Assets (ROA) is 8.54% as of 2026-06-30.
What is JAZZ's ROIC (return on invested capital)?
Jazz Pharmaceuticals plc (JAZZ)'s trailing twelve month Return on Invested Capital (ROIC) is 11.51% as of 2026-06-30.
What is JAZZ's EV/EBITDA?
Jazz Pharmaceuticals plc (JAZZ)'s trailing twelve month EV/EBITDA is 19.22x as of 2026-06-30.